Replimune Group Inc (NAS:REPL)

$ 8.49 0.63 (8.01%) Market Cap: 521.41 Mil Enterprise Value: 176.62 Mil PE Ratio: 0 PB Ratio: 1.39 GF Score: 30/100

Replimune Group Inc at JPMorgan Healthcare Conference Transcript
Jan 08, 2024
Replimune Group Inc RP1 Program Update Call Transcript
Dec 05, 2023
Replimune Group Inc at JPMorgan Healthcare Conference Transcript
Jan 09, 2023
Replimune Group Inc to Host Virtual Investor Event Transcript
Dec 07, 2022
Replimune Group Inc To Host Investor Day Transcript
Mar 30, 2022
Replimune Group Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 10, 2022
Replimune Group Inc Annual Shareholders Meeting Transcript
Sep 08, 2021
Replimune Group Inc Virtual Investor Event Corporate Call Transcript
Jun 03, 2021
Replimune Group Inc at Barclays Global Healthcare Conference (Virtual) Transcript
Mar 11, 2021
Replimune Group Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 12, 2021
Replimune Group Inc to Provide Phase 1/2 Clinical Data Update on Patients with Melanoma and Non-Melanoma Skin Cancers - Conference Call Transcript
Jun 03, 2020
Replimune Group Inc at JPMorgan Healthcare Conference Transcript
Jan 15, 2020

Replimune Group Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 12, 2021 / 10:20PM GMT

Release Date Price: $42.5 (+1.41%)

Transcript 8-K

Anupam Rama

JPMorgan Chase & Co, Research Division - VP and Analyst

Welcome, everyone, to the 39th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Tessa Romero and Matt Bannon from the team. The next presenting company is Replimune, and speaking on behalf of the company, we have CEO, Philip Astley-Sparke. (Operator Instructions) With that, I can pass it over to Philip.

Philip Astley;Sparke

Replimune Group, Inc. - CEO & Director

Thank you, Anupam. Safe harbor on Slide 2 and starting on Slide 3 for the Replimune overview. Replimune was founded to realize the full potential of oncolytic immunotherapy. Our products are designed to maximally activate a systemic immune response against a patient's cancer, and we believe that our programs will become the second cornerstone of immuno-oncology.

RP1, our lead asset, principally targets immune-responsive tumor types and having generated strong data sets in PD-1 naive cutaneous squamous cell carcinoma

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.